Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of peanut allergies
3.2.1.2 Increasing approvals for immunotherapeutic treatments
3.2.1.3 Increasing investments for developing new treatment modalities
3.2.1.4 Rising awareness towards timely treatment of peanut allergies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of immunotherapeutic treatments
3.2.2.2 Safety issues during initial treatment phase
3.3 Growth potential analysis
3.4 Future market trends
3.5 Regulatory landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Injectable
5.3 Oral
5.4 Other routes of administration
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Epinephrine
6.3 Antihistamines
6.4 Immunotherapies
6.5 Other drug classes
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Other distribution channels
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Adamis Pharmaceuticals Corporation
9.2 AdvaCare Pharma
9.3 Aimmune Therapeutics Inc.
9.4 Amneal Pharmaceuticals LLC
9.5 Amphastar Pharmaceuticals, Inc.
9.6 CVS Pharmacy
9.7 DBV Technologies
9.8 Kaleo
9.9 Mylan N.V.
9.10 Novartis AG
9.11 Pfizer Inc.
9.12 Regeneron Pharmaceuticals Inc.
9.13 Sanofi
9.14 TerSera Therapeutics LLC
9.15 Teva Pharmaceuticals Industries Ltd.
